DESYREL (trazodone hydrochloride) by Pragma Bio is trazodone's antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the cns. First approved in 1981.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
DESYREL (trazodone hydrochloride) is an oral small-molecule antidepressant approved in 1981 that primarily treats major depressive disorder. The drug works through dual mechanisms as both a selective serotonin reuptake inhibitor and 5-HT2 receptor antagonist, though its precise antidepressant mechanism remains incompletely understood. It enhances serotonergic activity in the central nervous system.
Product is 2.7 years from loss of exclusivity with moderate competitive pressure (15 competitors), signaling transition planning and potential team restructuring.
trazodone's antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS. Trazodone is both a selective serotonin reuptake inhibitor (SSRI) and a 5HT2 receptor antagonist and the net result of this action on serotonergic…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese
PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
Worked on DESYREL at Pragma Bio? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~3 years — strategic planning for patent cliff underway
Working on DESYREL offers experience in mature-product lifecycle management, generic defense strategy, and off-label positioning within a legacy franchise. Career value lies in navigating LOE transition and evaluating strategic options (authorized generics, brand extension, divestiture) rather than growth-phase innovation.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo